NUVECTIS PHARMA INC
NVCTNASDAQTrading Snapshot
- Day Range
- $19.35 – $19.82
- 52-Week Range
- $5.55 – $29.28
- Volume
- $2.34B
- Avg Volume
- $2.87B
- Shares Outstanding
- 31.5M
- Next Earnings
- Oct 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $308M
- Last Q Revenue
- $73M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.20
- Dividend Yield
- —
Why Investors Own NVCT
- ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NUVECTIS PHARMA INC
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is unchanged from the same period last year.
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNHCiprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under reviewCiprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantag
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNHCiprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under reviewCiprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantag
Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria
Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.